PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50123C00056 — ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND…

ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND… is a federal NONE award for Department of Health and Human Services (HHS) held by MODEX THERAPEUTICS LLC. Estimated value $110M ($103.5M obligated). Current period of performance ends Feb 29, 2028 (potential Jan 18, 2030). Last award drew 1 bidder. Place of performance: NATICK, MA. Related solicitation BAA-18-100-SOL-0003.

$110M
Estimated Value
$103.5M
Obligated
Feb 29, 2028
PoP End / Expires
1
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

MODEX THERAPEUTICS LLC holds $103.5M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Feb 29, 2028 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75A50123C00056
AgencyDepartment of Health and Human Services (HHS)
IncumbentMODEX THERAPEUTICS LLC
UEICDVMNSMRDTW8
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN13
Place of performanceNATICK, MA
Related solicitationBAA-18-100-SOL-0003
PoP end (current)Feb 29, 2028
PoP end (w/ options)Jan 18, 2030
Obligated$103.5M

ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA.

Recompete timing

Public
Expiring in 562 days

Current PoP ends Feb 29, 2028 (562 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Aug 29, 2026.

Watch this contract — one email →

Incumbent footprint

Public record

MODEX THERAPEUTICS LLC$103.5M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$103.5M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open MODEX THERAPEUTICS LLC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50123C00056?

75A50123C00056 (ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND…) is a Department of Health and Human Services (HHS) award with an estimated value of $110M, currently held by MODEX THERAPEUTICS LLC. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50123C00056?

MODEX THERAPEUTICS LLC is the incumbent with $103.5M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Feb 29, 2028.

When does 75A50123C00056 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 29, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50123C00056